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ABSTRACT. The limited treatment options against influenza virus along with the growing public health 
concerns regarding the continuous emergence of drug-resistant viruses make essential the development of new 
anti-flu agents with novel mechanisms of action. One of the most attractive targets is the interaction between 
two subunits of the RNA-dependent RNA polymerase, PA and PB1. Herein we report the rational design of 
hybrid compounds starting from a 3-cyano-4,6-diphenylpyridine scaffold recently identified as disruptor of 
PA-PB1 interactions. Guided by the previously reported SAR data, a library of amino acid derivatives was 
synthesized. The biological evaluation led to the identification of new PA-PB1 inhibitors, that do not show 
appreciable toxicity. Molecular modeling shed further lights on the inhibition mechanism of these compounds. 
KEYWORDS: anti-influenza; PA-PB1; RdRp; amino acid coupling; SPPS; diphenyl-pyridine. 
INTRODUCTION. Influenza, also known as flu, is an acute respiratory illness caused by the infection of 
viruses which belong to the Orthomyxoviridae family. These pathogens are enveloped viruses containing a 
single-stranded, negative-sense and segmented RNA genome and are classified in A, B, C and D,[1,2]  
according to the antigenicity of their nucleoprotein (NP) and matrix protein 1 (M1).[3] Infections by influenza 
A (FluA) and B (FluB) virus are the most relevant ad occur globally as epidemics (seasonal flu almost every 
winter) or as more sporadic pandemics caused by always new and very different A viruses. Seasonal flu 
accounts for a large number of cases worldwide each year (between 9.2 and 35.6 million; 5–10% of adults and 
20–30% of children)[4] and can cause severe illness especially in population at high risk for influenza-related 
complications (e.g. immunocompromised, patients with chronic diseases and paediatric and old people), 
resulting in hospitalization and death.[5] 
Influenza viruses undergo continuous antigenic drifts and sporadic antigenic shifts that result in minor and 
major antigenic changes of the viral surface glycoproteins and allow the viruses to evade the pre-existing host 
immune response. For this reason, influenza vaccines must be constantly reformulated and fail to provide 
protection against novel pandemic strains.[6–8]Only two classes of chemotherapeutics are currently available: 
the M2-blockers, such as amantadine and rimantadine, that inhibit the replication by blocking the M2 proton 
channel[9] and the neuraminidase inhibitors, such as zanamivir and oseltamivir, that prevent virus release from 
infected cells. The increase of chemoresistance,[10–22] the serious side effects of the current anti-flu drugs[23] 
and the difficulty of production of cross-protective vaccines, make current therapeutic armamentarium limited 
and poorly effective,[24] molecules to fit.[29,55] After first attempts of PPI inhibition through PB1-derived 
peptides,[44,51,53,56] several different libraries of small molecules were investigated by in silico screenings, 
biochemical assays and rational design.[50,52,57–65] 
In the last few years, our research group identified benzofurazan derivatives as inhibitors of PA–PB1 
interaction through high throughput screening (HTS) and these compounds were characterized by an ELISA-
based assay followed by plaque reduction assay (PRA) on FluA/WSN/33 (H1N1)-infected MDCK cells. This 
led us to identify the hit compound 1 (Figure1), showing micromolar antiviral activity (EC50 = 5 μM), but 
cytotoxicity in MDCK cells (CC50 = 20 μM).[66] In order to explore the SARs and improve the selectivity 
index (SI) and water solubility, a large library of benzofurazan derivatives was synthesized and tested, giving 
a more potent compound 2 (IC50 = 35 μM, EC50 = 1 μM), but still cytotoxic (CC50  = 40 μM) (Figure 1).[67] 
Despite the good anti-flu activity, this class of compounds was found to be unsuitable for further development 
because of its poor SI. A model of the PA-PB1 complex was built based on PDB IDs 3CM8[68] and 
2ZNL[44]and it was used to perform a MD simulation to identify the hot-spot residues for the inhibition. The 
following high throughput docking approach (a consensus docking protocol combining Glide[69] and 
Gold[70] programs)[67] together highlighting the need for new targets discovery and exploitation. Because of 
its critical role in FluA infection and its high amino acid conservation,[25–28] the viral polymerase is widely 
recognized as one of the most promising anti-flu targets.[29–32] 
The RNA-dependent RNA polymerase (RdRp) is a heterotrimeric complex composed of polymerase acidic 
protein (PA), polymerase basic proteins 1 and 2 (PB1 and PB2, respectively) with a combined mass of 
approximatively 250 KDa. [33,34] The enzymatic complex is associated to the NP-encapsulated RNA strand 
to form the viral ribonucleoprotein complex (RNP).[33,35] It plays a key role in the viral life cycle, as it is 
directly required for both transcription and replication.[25,26,33,36–41] The Flu RdRp cleaves the 5′-methyl 
cap from the host pre-mRNA and uses this capped structure as a primer for the synthesis of the viral mRNA 
by a cap-snatching mechanism. The polymerase complex also catalyses the genome replication, generating a 
positive-sense complementary RNA (cRNA), a replicative intermediate that serves as a template for the 
synthesis of more copies of the viral genomic segments (vRNA).[33,34,42,43] The polymerase catalytic site 
is in PB1; PB2 includes the capped-RNA recognition domain, required for generation of the primer for 
transcription, while PA is involved in the complex assembly.[42,44–46] Only if correctly assembled RdRp can 
work and the virus can replicate its genome.[41,44,47,48] Indeed, even if so far the search for new antiviral 
targets has been mostly focused on the PA endonuclease active site, PB2 cap-binding domain and PB1 
subunit,[49] a very attractive strategy could be the disruption of RdRp complex assembly through protein-
protein interaction (PPI) inhibition. In fact, PPIs represent crucial events in many biological processes under 
both physiological and pathological conditions. In particular, crystallization studies have revealed that PA-
PB1 interaction may be a very promising druggable target, [29,49–52] because of the high degree of 
conservation of several interface residues among FluA, FluB and FluC,[27,53,54] that suggests that its 
inhibitors may be active against many viral subtypes and less prone to drug-resistance, and because of the little 
size of the specific interface that allows small  
with ELISA evaluation revealed the 3-cyano-4,6-diphenyl-pyridine scaffold as a promising potential inhibitor 
of the PA−PB1 complex by mimicking the hydrophilic N-terminal portion of PB1 (residues 1−4) and the most 
important interactions with the C-terminal domain of PA. Compounds 3 and 4 (Figure 1), showed the best 
activity profile.[63] The following validation of the reliability of the old homology model was performed 
through comparison with the more complete X-ray structure of FluA H17N10 RdRp (PDB ID: 4WSB)[41] 
and the superposition in the PB1-binding site region.[71] Chemical modifications aided by molecular modeling 
studies allowed us to make preliminary SAR considerations and to identify some compounds (5 and 6, Figure 
1) as promising anti-flu agents, even if they suffer from low water solubility that implied the design and 
validation of a new serum-free ELISA.[71] 
 
Figure 1. Structures of compounds 1-6 from previous works.[63,66,67,71] 
 
DISCUSSION. The biological evaluation of the compounds described above[71] allowed us to confirm this 
novel class of diphenyl-pyridine derivatives as promising and non-toxic PA-PB1 disrupting RdRp inhibitors, 
and to determine preliminary SARs. In order to increase the affinity to the PB1 binding site, a rational design 
of new derivatives was performed. 
As already discussed, this library of derivatives contains a scaffold that directly competes and displaces the N-
terminal portion of PB1 (PB1N). Indeed, the overlap of PB1N in the X-ray crystallography structure with the 
docking pose of compound 3 (Figure 2) revealed that the cyano-pyridine core fits very well with a central 
region of PB1N, but the compound fails in establishing crucial interactions instead made with PA by the three 
terminal amino acids (Met1-Asp2-Val3) of PB1N peptide.[63,71] 
 
Figure 2. Superimposition of the crystallographic poses of PB1N and the docking pose of compound 3, a representative 
molecule of the cyano-pyridine library, with the interaction protein region I, II and III. PB1N is showed as grey cartoon 
and the last three amino acids (Met1-Asp2-Val3) are represented by sticks. The three amino acids of PA (Gln408, Asn412 
and Ile621) that interact with the C2 chain are represented by green sticks and labelled. 
 
With the aim to enhance the ability of our compounds to completely displace PB1 and increase their affinity 
toward the target protein PA, a hybrid derivative, combining the cyano-pyridine core linked to the PB1N last 
peptide side chain (Met-Asp-Val) has been designed and docked into the PB1 binding site on PA. The rational 
design was performed choosing the cyano-pyridine ring of compound 3 as the nucleus to which specific amino 
acids were added on the C2 side chain. Since the majority of the first virtual screening hits[63] were 
characterized by a p-methyl group substituent on the C4 phenyl ring, this was maintained.  
At first, the hybrid Target Compound (see structure in Scheme S1 of Supplementary information) was 
planned with the molecule bearing the peptide as N-terminal amine. Despite a lot of attempts (some of which 
are reported in Supplementary information), the synthesis of this first designed Target Compound has proven 
to be difficult to achieve; so we decided to prepare its “inverted amide”, inserting the peptide as C-terminal. 
This modification was shown to be not relevant for the interaction with the most important residues of PA, 
confirming a sufficiently similar docking pose.  
In fact, from docking simulations, emerged that both the first designed Target Compound and the compound 
with the inverted amide 11 (structure reported in Figure 3-4) were able to maintain the characteristic 
interactions of the cyano-pyridine derivatives with Lys643 and Gln408 of PA also establishing two additional 
hydrogen bonds with Val621 and Asn412 through the backbone of the terminal Asp and Val amino acids 
(Figure 3A). The superimposition of the docking pose of compound 11 binding mode with the PB1N fragment 
demonstrated a good overlap of the tripeptide region (Figure 3B). 
  
Figure 3. Docking pose of compound 11 in PA (Panel A) and superimposition of docking poses of compound 11 and 
PB1N (Panel B). PA residues are represented by green sticks and PB1N is represented in grey. 
 
The adducts with valine, valine-aspartate and valine-aspartate-methionine methyl esters (7a, 9 and 11 
respectively, shown in Figure 4) were synthesized in order to explore the chemical space around the C2 side 
chain. We decided to introduce amino acids as esters because they are more permeable through membranes 
than the correspondent free acids.[72,73] Compound 11 turned out to be a weak inhibitor, while more 
interesting activity profiles have been revealed for compounds 7a and 9. They showed a relevant discordance 
between the low PA-PB1 interaction inhibition and the good intracellular activity, but minireplicon assays 
confirmed the on-target activity (data reported in Table 1), suggesting a possible enzymatic hydrolysis in the 
cell. To confirm this hypothesis, the free acid of Val and Val-Asp adducts were synthesized, through a 
controlled hydrolysis in basic conditions, yielding 8 and 10 respectively. The biological data of these 
derivatives seem to confirm that they are the actual responsible for the antiviral activity, as expected. The good 
results of Val adducts 7a and 8 are in agreement with experimental data previously reported by Wunderlich et 
al[74] that revealed Val3 on the PB1 peptide as one of the most important residues for the interaction with PA, 
exhibiting the lowest binding free energy,[63] thus suggesting that its displacement could inhibit the RdRp 
heterodimerization.  
Encouraged by these findings, we decided to investigate the effects of other amino acids at the protein-protein 
surface of the target through the addition of different L-amino acids as methyl esters (Leu, Ile, His, Arg, Phe, 
Tyr, Glu: compounds 7b-h), whose structures are reported in Figure 4, through the validate synthetic 
procedure of 7a (Scheme 2). Leucine (7b) and isoleucine (7c) have been chosen as hydrophobic good 
replacement of valine, while the other residues have been selected as representatives of all the existing classes 
of amino acids to investigate about the possible interactions of their different functions. Histidine (7d) and 
arginine (7e) bear a positive charge at physiological pH, phenylalanine (7f) and tyrosine (7g) are characterized 
by aromatic lateral chains that can interact with the protein region I and glutamate (7h), if hydrolysed, bears 
negative charges that could enhance the affinity of ligands towards the protein. Molecular docking studies 
were then carried out to investigate the possible binding mode of these molecules within the PB1 binding site 
of PA, while molecular dynamics (MD) simulations were performed to identify the molecular determinants 
responsible for in vitro PA-PB1 PPI inhibition. 
 Figure 4. Synthesized hybrid compounds 7-11. 
CHEMISTRY. The first part of the synthetic work has been devoted to the set-up of a fast and high yielding 
procedure for the preparation of the 4,6-diphenyl-3-cyanopyridinic nucleus. Starting materials were 
acetophenone and p-tolualdehyde which were reacted via base catalysed Claisen-Schmidt condensation 
reaction, affording the chalcone derivative 12.[75–77] This acts as Michael acceptor and the dihydropyridine 
derivative 13 was obtained through a Hantzch-type cyclization of 12 with cyanothioacetamide using sodium 
methoxide as a base.[78] Compound 13 was aromatized with 2,3-dichloro-5,6-dicyano-p-benzoquinone 
(DDQ) affording 2-mercapto derivative 14.[79] Then, a nucleophilic substitution of 2-bromoacetic acid was 
carried out in DMF using potassium hydroxide as base affording the cyano-pyridinic core 15 (Scheme 1). 
 
Scheme 1. Synthesis of cyano-pyridinic core. Reagents and conditions: (i) NaOH 4N, abs EtOH, N2, r.t., 2 h; (ii) 
Cyanothioacetamide, Na0, dry MeOH, N2, ref., 90 min; (iii) DDQ, DCM, r.t., 3 h; (vi) Bromoacetic acid, KOH 10%, 
DMF, r.t., 4 h. 
To synthesize the mono amino acid adducts 7a-h, we used the same amidation procedure with EDC (1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide) and HOBt (hydroxybenzotriazole) as coupling agents[78] and 
racemization suppressors,[80] dry DIPEA (N, N- diisopropylethylamine), carboxylic acid 15 and the 
appropriate amino acid methyl ester in dry DMF. Methyl ester 7a was hydrolysed in mild basic conditions 
furnishing the free carboxylic derivative 8 (Scheme 2). 
 Scheme 2. Synthesis of mono-amino acid adducts 7a-h and 8. Reagents and conditions: (i) 15, EDC, HOBt, dry DIPEA, 
dry DMF, N2, 0 °C to r.t., 3 h; (iia) only for 7a: NaOH 1N, THF/EtOH/H2O, r.t., 30 min. R is the lateral chain of the 
appropriate amino acid. 
The synthetic route to obtain di-amino acid adduct 9 is shown in Scheme 3. The Val-Asp dipeptide 16 was 
synthesized in solution phase through the previous described amidation procedure with Fmoc-L-valine and L-
aspartic acid methyl ester. Dipeptide 16 was subjected to the cleavage of the Fmoc protecting group with 
sodium azide (NaN3). The free amine 17 was then coupled with acid derivative 15 furnishing the di-amino acid 
adduct 9. Eventually, the ester functions of 9 were hydrolysed by using a sodium hydroxide solution affording 
the bicarboxylic acid derivative 10. 
 
Scheme 3. Synthesis of di-amino acid adducts 9 and 10. Reagents and conditions: (i) EDC, HOBt, dry DIPEA, dry DMF, 
N2, 0 °C to r.t., 8 h; (ii) NaN3, DMF, 50 °C, 5 h; (iii) EDC, HOBt, dry DIPEA, dry DMF, N2, 0°C to r.t., 4 h; (iv) NaOH 
1N, THF/EtOH/H2O, r.t., 30 min.  
The synthesis of the tri-amino acid adduct 11 required the preparation of the tripeptide Val-Asp-Met, that was 
performed in solid phase through the Fmoc strategy and is reported in Scheme 4. MW-SPPS (Microwave Solid 
Phase Peptide Synthesis) was conducted by using an automated peptide synthesizer, that was charged with a 
resin (Wang resin) bearing the last amino acid of our tripeptide, L-methionine, covalently linked. Prior to use, 
the resin was swallowed for 2 hours in DMF. In addition to resin and solvents (DMF and DCM), the instrument 
was also charged with the other two protected amino acids (Fmoc-L-Asp-(OtBu) and Fmoc-L-Val), the 
coupling activators (HOBt and HBTU), a base (DIPEA) and a deprotection solution (20% piperidine in DMF). 
At the end of the deprotection and coupling cycles, we obtained the resin-bounded tripeptide 18, which was 
manually cleaved to avoid the employment of corrosive trifluoroacetic acid (TFA) inside the instrument. The 
cleavage of the resin was performed through a solution of TFA, H2O and triisopropylsilane (TIPS) as 
scavengers for the reactive species produced during resin cleavage, and dithiotreithol (DTT) to avoid 
methionine oxidation. Under these acid conditions the tert-butyl ester in the aspartate lateral chain was 
hydrolysed furnishing the resin-free tripeptide 19 which was used in the next step without further purification. 
Then the methyl esterification of dicarboxylic functions of 19, accomplished by treating it with a methanolic 
solution of freshly distilled thionyl chloride (SOCl2), was necessary to avoid side reactions in next steps. The 
reaction was carried out at room temperature and with controlled equivalents of SOCl2 in order not to allow 
the acid-catalysed racemization of the methionine stereocenter. Dimethyl ester tripeptide 20 was then 
deprotected from the Fmoc group furnishing the free amine 21 which was coupled with carboxylic core 15 
affording the final tri-amino acid adduct 11. 
Scheme 4. Synthesis of tri-amino acid adduct (11). Reagents and conditions: (i) at Microwave Automated Peptide 
Synthesizer; (ii) TFA/TIPS/H₂ O/DTT, N₂ , 3 h; (iii) SOCl2 dist., dry MeOH, N₂ , r.t., 6 h; (iv) NaN3, DMF, 50 °C, 4 h; 
(v) 15, EDC, HOBt, dry DIPEA, dry DMF, 0 °C for 30 min., r.t., 12 h. 
 
BIOLOGY. Amino acid derivatives 7-11, and the intermediates 15, 23 and 24 (the synthetic schemes of these 
last two compounds are reported in Supplementary Information) were tested as inhibitors of the PA−PB1 
interaction. The in vitro biological evaluation of these compounds was conducted through enzyme-linked 
immunosorbent assays (ELISA) and plaque reduction assays (PRA) in Madin−Darby canine kidney (MDCK) 
cells infected with FluA virus (A/PR/8/34 strain). The ELISA PA−PB1 interaction assay can measure the 
physical inhibition between the two subunits, providing IC50 values. This assay was performed using the 
PB1(1−15)-Tat peptide[56] as a positive control for inhibition. The PRA evaluates the block of the viral 
replication and includes oseltamivir carboxylic acid (OSV), the active form of oseltamivir (NA inhibitor) and 
ribavirin (RBV) as positive controls. Cytotoxicity was assessed both in MDCK and in HEK 293T cell lines by 
MTT assays.  
Moreover, to confirm the mechanism of action implied by the ELISA interaction assay, the ability of the most 
interesting compounds (7a, 7c, 8, 9, 15, 24) to inhibit FluA RdRp enzymatic activity in a cellular context was 
assessed by minireplicon assays in transfected HEK 293T cells, using ribavirin (RBV)[81] as a reference drug, 
since it acts as RNA synthesis inhibitor thanks to its guanosine-like structure. In Table 1 all the biological data 
are reported. 
The tripeptide derivative (11) showed a weak inhibitory activity (IC50 = 68±14 µM) but such an activity is not 
retained in cells (EC50 > 100 µM in PRA).  
The biological data for the methyl esters 9 and 7a, in particular the minireplicon assay results for 7a, confirmed 
our hypothesis of a possible intracellular hydrolysis, so one could assume that their actual target is the PA-PB1 
interaction, considering similar or lower EC50 values in minireplicon assays when compared to the ones 
observed in PRAs.   
In fact, the free acid adduct 10 inhibited the interaction between PA and PB1 with a IC50 value of 77±9 µM, 
while it was less active in blocking viral replication in infected cells (EC50 = 100 µM in PRA), likely due to its 
inability to pass through the membranes. In contrast, the correspondent methyl ester 9 exhibited a good activity 
in cell, according to PRA and minireplicon results (EC50 = 49±8 µM and EC50 = 59±18 µM, respectively), but 
a low ability to disrupt the PA-PB1 interaction in ELISA (IC50 = 143±1 µM).  
As far as the valine adducts, the methyl ester derivative 7a seemed to have a similar biological profile than the 
di-peptide adduct 9, showing a good antiviral activity (EC50 = 52±2 µM in PRA) and confirming the on-target 
activity in minireplicon assays (EC50 = 41±16 µM), while a high IC50 value of 167±20 µM was detected. The 
free acid derivative 8 showed similar EC50 values in PRA and in minireplicon experiments (50±7 and 77±14 
µM, respectively) and a more potent activity in ELISA (IC50 = 76±16 µM) when compared to its methyl ester 
correspondent 7a. 
Surprisingly, although the small difference in the side chain, leucine (7b) and isoleucine (7c) adducts were 
found to have very different biological profiles: 7b appeared to have a low ability to disrupt the PA-PB1 
interaction (IC50=149±15 µM), but showed a weak inhibitory activity in infected cells (EC50 = 97±9 µM; while 
7c had a very promising antiviral activity in infected cells (EC50 = 39±2 µM in PRA) and likely acted by 
inhibiting the PA-PB1 PPI, as suggested by both the ELISA (IC50 = 36±3 µM) and the minireplicon assays 
(EC50 = 53±16µM). The histidine derivative (7d) resulted to have good activity in the ELISA experiments (IC50 
= 32±7 µM), but, unfortunately, a high cytotoxicity was detected (CC50 = 152±3 µM in MDCK cells). The 
arginine and the tyrosine adducts (7e and 7g respectively) were effective as disruptors of the target interaction, 
with IC50 values of 48±8 and 18±5 µM, respectively, but did not retain the antiviral activity in cells (EC50 > 
100 µM). A particular case is the one of the phenylalanine derivative (7f) that seems not to have affinity with 
PA (IC50> 200 µM), but in infected cells was active with an EC50 value of 68±10 µM in PRA, perhaps after 
the ester hydrolysis or through an off-target mechanism of action. At the end, the glutamate derivative (7h) is 
found to be inactive. 
All tested compounds were non cytotoxic in MDCK and HEK 293T cells (CC50 > 200 µM) apart from 7d.  
Comparing our best compound (7c) to the previous published compound 5, we can observe a similar ability to 
disrupt the PA-PB1 interaction in ELISA. Moreover, even if compound 5 is a very potent antiviral agent with 
an EC50 of 9.2±0.7 µM in PRA, its activity is probably due to other additional modes of action as revealed by 
minireplicon assays (EC50 = 86.6±15 µM).  
The intermediates 15, 23, 24 (the structures of the two last compounds are reported in Supplementary 
Information) were also tested: while the amine 23 resulted inactive, the acid 15 and the amide 24 showed 
interesting activity profiles, even if a low toxic behaviour in HEK 293T cell line was detected. 
 
Table 1. Biological profiles of the synthesized compounds 7-11, 15, 23 and 24. 
Compound 






MTT in  





MTT in  
HEK 293T cells  
CC50 [µM] c,e 
7a 167 ± 20 52 ± 2 210 ± 8 41 ± 16 > 250 
7b 149 ± 15 97 ± 9 215 ± 28 - - 
7c 36 ± 3 39 ± 2 >250 53 ± 16 229 ± 12 
7d 32 ± 7 80 ± 6 152 ± 13 - - 
7e 48 ± 8 >100 >250 - - 
7f >200 68 ± 10 240 ± 18 - - 
7g 18 ± 5 >100 >250 - - 
7h 187 ± 14 >100 >250 - - 
8 76 ± 16 50 ± 7 > 250 77 ± 14 250 
9 143  ± 17 49 ± 8 > 250 59 ± 18 > 250 
10 77 ± 9 100 > 250 - - 
11 68 ± 14 >100 > 250 - - 
15 56 ± 5 65 ± 11 > 250 43 ± 14 218 ± 21 
23 >200 > 100 > 250 - - 
24 102 ± 18 41 ± 5 > 250 65 ± 14 218 ± 21 
5 71 35.2 ± 5.1 9.2 ± 0.7 >250 86.6 ± 15.0 > 250 
PB1(1−15)-Tat peptide 31.7 ± 10.8 49.7 ± 5.1 > 250 15.5 ± 2.6 > 250 
OSV - 0.015 ± 0.006 > 250 - > 250 
RBV - 12.8 ± 2.1 > 250 23.8 ± 4.5 > 250 
-: not determined. aActivity of the compounds in the ELISA PA−PB1 interaction assay. Values represent the compound 
concentration (in μM) that reduces the interaction between PA and PB1 by 50% (IC50). bAntiviral activity of the 
compounds in plaque reduction assays against the Flu A/PR/8/34 strain. Values represent the compound concentration 
(in μM) that inhibits 50% of plaque formation (EC50). Compound concentrations higher than those reported could not be 
tested in PRA due to cytotoxicity. cCytotoxicity of the compounds exhibited in MTT assays. Values represent the 
compound concentration (in μM) that causes a 50% decrease in cell viability (CC50). The CC50 were assessed in MDCK 
and HEK 293T cells. dThe EC50 values represent the compound concentration that reduces by 50% the activity of FluA 
virus RNA polymerase in HEK 293T cells. eAll values represent the means ± SD of data derived from at least three 
independent experiments in duplicate. Reference compounds are the previous described compound 5, PB1(1−15)-Tat 
peptide, oseltamivir carboxylic acid (OSV) and ribavirin (RBV). 
MOLECULAR MODELING. The ELISA PA−PB1 interaction assay provided a direct measure of the PA-
PB1 PPI inhibition by test compounds. Here, to add further insights into the inhibition mechanism, we carried 
out molecular modeling investigations. First, the possible binding mode of compounds listed in Table 1 to the 
PB1 binding site of PA was predicted by molecular docking, which was performed with the GOLD program 
(GoldScore function)[82] according to previous works.[63,71] Notably, all compounds and intermediates 
showed to fit the PB1 site of PA with a binding geometry that is highly comparable each other, as well as to 
the binding mode already described above for compound 11 and the reference inhibitor PB1N (see Figure 2 
and Figure 3). The binding mode of tested compounds is described in Supplementary information. However, 
probably because of the narrow activity range observed in the ELISA assay (Table 1), any attempt to correlate 
the ligands’ scores with experimental data was unsuccessful (data not shown). Therefore, to identify the 
possible molecular determinants responsible for strong inhibition in the ELISA assay, we carried out molecular 
dynamics (MD) investigations on the docking-based complexes between PA and compounds 7g and 7f (Figure 
4). Indeed, these two molecules differ each other only for the –OH phenol group in 7g (L-Tyr residue) that is 
missing in 7f (L-Phe residue), but were notably different in the ELISA experiment, as 7g proved the most 
potent PA-PB1 inhibitor of the tested set while 7f was inactive up to 200 µM concentration. Thus, they 
represent a suitable model system to challenge MD simulations. The representative docking complex of 7g 
and 7f was solvated in a box of water molecules and was energy minimized, heated and equilibrated in density 
as described previously,[83,84] before to run 250 ns of unrestrained MD simulations. Cluster analysis 
performed on the whole MD production trajectories coupled with visual inspection clearly indicated that 7g is 
stable in the PB1 binding site, with a conformation that is highly consistent to that identified by molecular 
docking (Figure 5A). The nitrile group of 7g establishes a H-bond interaction with the side chain of Lys643 
(to allow comparison with results described in previous works [63, 71] residue numbering follows the sequence 
of A/Wilson-Smith/1933 H1N1 strain). The two phenyl rings of the 3-cyano-4,6-diphenylpyridine scaffold are 
included in a hydrophobic cleft bounded by Pro625, Phe658, Leu666, Trp706, Phe707, and Phe710. The 
peptide moiety notably overlaps with the crystallographic pose of the N-terminal end of PB1,[26] and 
establishes a network of H-bonds. First, the amide bond contacts Glu623, and Gln408 (bridged by a water 
molecule, see Figure 5A) that was already highlighted in prior works [63, 71] as a crucial residue for the 
binding of PA-PB1 inhibitors. The L-Tyr side chain of 7g is accommodated in a hydrophobic sub-pocket of 
PA where it interacts with Asn412 (bridged by a water molecule), Ser415, and Lys635. It is worth mentioning 
that these three H-bonds are established by the –OH phenol group of 7g, which is missing in 7f. Different from 
the docking pose (Supplementary information), the peptide moiety of 7f bends back towards the hydrophobic 
cleft of PA thus assuming a bad placement as described previously (Figure 5B).[71] Moreover, in this 
conformation 7f is unable to establish most of H-bond interactions with PA key residues with the only 
exception of a single H-bond to Lys635. The different binding conformation and interaction network between 
these two compounds might explain their opposite behaviour observed in the PA−PB1 interaction assay 
(ELISA). To further substantiate this hypothesis, we estimated the ligand’s theoretical affinity by means of the 
MM-GBSA approach.[85] Delta energy calculations clearly showed that the different binding conformation is 
associated to a significantly different theoretical affinity, as reported in Table 2, which suggests that ligand 
affinity is mainly related to enthalpy contributions. In summary, this molecular modeling investigation added 
further insights to the inhibition mechanism of tested molecules and might drive the design of ligands with 
enhanced affinity for PA.  
 
 
Table 2. Delta energy of binding of 7g and 7f to PA estimated by the MM-GBSA approach. 
Compound MM-GBSA (kcal/mol) ± SEMa 
7g -40.78 ± 1.12 
7f -27.65 ± 0.78 
aStandard Error of the Mean 
 
 
Figure 5. Binding pose of 7g (panel A) and 7f (panel B) extrapolated from the most representative cluster of MD frames. 
The protein is shown as green cartoon, residues within 4 Å from the ligand are showed as lines, residues H-bonded to the 
ligand are showed as sticks and are labelled. Non-polar H atoms are omitted. Bridged water molecules are showed as red 
spheres, while the bulky solvent is omitted. 7g is shown as cyan sticks, 7f as white sticks. H-bond interactions are 
highlighted by grey dashed lines. 
CONCLUSIONS. In the frame of the limited armamentarium of drugs for the treatment of Flu infections 
together with the chemo-resistant phenotypes increasing, the search for novel antivirals with innovative mode 
of action became imperative. In recent years, the viral polymerase has proved to be an attractive target for drug 
design, although the current efforts led to quite toxic compounds. In particular, some research groups have 
been interested in the development of small molecules able to interfere with the correct assembly of RdRp 
complex, through the inhibition of the interaction between PA and PB1, two of its subunits. In this work, 
starting from previously published findings, a rational drug design led us to synthesize hybrid compounds 
characterized by the diphenyl-pyridine nucleus, identified as promising inhibitor of the above mentioned PPI, 
and the same last amino acids side chain of PB1N (Met-Asp-Val) in C2. Indeed, we planned the synthesis of 
the tri-peptidic (11), di-peptidic (Val-Asp, 9) and the mono-amino acid (Val, 7a) derivatives as methyl esters 
to ensure a higher passive membrane permeability. Biological data results highlighted a major anti-flu activity 
(EC50 in PRA) of 9 and 7a, not correlated to the low enzymatic inhibition (IC50 in ELISA). To better investigate 
this discrepancy, minireplicon experiments were performed, allowing us to confirm the PA-PB1 interaction 
disruption as the main target of our compounds. Moreover, we hypothesize that these methyl ester derivatives 
could be hydrolysed in cell, giving the corresponding free acids. In fact, the synthesized 10 and 8 (free acid 
dipeptide and mono-amino acid derivatives, respectively) showed a better IC50 when compared to that of 9 and 
7a. Notably, valine derivatives 7a and 8 emerged as new hit compounds for further optimization. Aimed by 
the exploration of the chemical space around the C2 of the diphenyl-pyridine core, novel mono-amino acid 
derivatives (7b-h) were synthesized and tested. Interestingly, the modulation in C2 of the starting chemical 
structures led to an increase in the on-target activity. In particular, the best results were achieved with the 
isoleucine derivative (7c) that exhibited a good biological profile with no cytotoxic behaviour. Molecular 
modeling simulations added further insights to the inhibition mechanism of these compounds, showing that 
enthalpy contributions (i.e. H-bond interactions with PA key residues) are crucial to achieve strong PA-PB1 
PPI inhibition in vitro. In summary, a new small library of hybrid derivatives endowed with anti-influenza 
activity was generated. Almost of all of these compounds were found to be not cytotoxic at high concentrations 
in the two cell lines used for testing and to inhibit actually the studied PPI. Moreover, we set up a quantitative 
four-step scaling-up procedure to synthesize the diphenyl-pyridine scaffold that might be helpful to expand the 
chemical class and to improve the inhibitory activity.  
 
MATERIAL AND METHODS 
1. COMPUTATIONAL SECTION 
The crystallographic structure of Influenza A virus PA (C-terminal region) in complex with PB1N coded by 
PDB ID: 4WSB,[44] which was already validated as docking receptor in a previous work, [71] was used as 
rigid receptor in molecular docking studies.[26] Tested compounds were designed by means of Maestro 
program, and docked by using the GOLD docking program with the GoldScore function.[82] The receptor’s 
site was centred on the carbon atom in position 2 of the indole ring of Trp706, and had a radius of 18 Å. The 
search efficiency of the Genetic Algorithm was increased up to 200%, while all other parameters were kept at 
their default values. MD simulations were carried out with Amber16, using the FF14SB force field for the 
protein and GAFF force field for small molecules.[86] Ligands partial charges were assigned at the am1-bcc 
level of theory. Each PA-ligand complex was solvated in a rectilinear box of TIP3P water molecules buffering 
8 Å from the protein surface. Na+ counter-ions were added to neutralize the total charge of the system. First, 
the water solvent was energy minimized for 500 steps with the steepest descent algorithm (SD) and 1500 steps 
with the conjugate gradient algorithm (CG); then, the whole system was energy minimized for 1000 steps SD 
and 4000 steps CG before to be heated up to 300 K in 100 ps (time-step is 2 fs). The heated system was 
equilibrated in density at constant pressure for 100 ps before to run an equilibration MD at constant pressure 
for 50 ns. Subsequently, unrestrained MD production was run for 250 ns at constant pressure. Analysis of MD 
trajectories, including cluster analysis, was carried out by cpptraj.[86] Graphics representations were drawn 
for clusters being representative of more than 60% of MD frames. 
 
2. CHEMISTRY SECTION 
All commercially available chemicals and solvents were used as purchased (Merck-Sigma Aldrich, Alfa-
Aesar). Anhydrous reactions were run under a positive pressure of dry nitrogen. Anhydrous solvents were 
prepared by distillation over the appropriate agent: DCM was dried over sodium hydride; THF was dried over 
sodium and benzophenone; MeOH and EtOH were dried over iodide and magnesium. Anhydrous DMF was 
used as purchased. Microwave reactions were conducted using a CEM Discover Synthesis Unit (CEM Corp., 
Matthews, NC). Chromatographic separations were performed on columns packed with silica gel (230-400 
mesh, for flash technique). TLC (thin layer chromatography) was carried out using Merck TLC plates silica 
gel 60 F254.. Melting points (Mp) were determined with a Büchi B-540 apparatus and are uncorrected. 1H NMR 
and 13C NMR spectra were recorded at 400 and 100 MHz respectively on a Bruker AC200F spectrometer and 
are reported in parts per million (δ scale) and internally referenced to the CDCl3, CD3OD or DMSO D6 signal, 
respectively at δ 7.26 ppm, 3.31 ppm and 2.50 ppm. Chemical shifts for carbon are reported in parts per million 
(δ scale) and referenced to the carbon resonances of the solvent (CDCl3 at δ 77.16, CD3OD at δ 49.00 ppm and 
DMSO D6 at 39.52 ppm). Data are shown as following: chemical shift, multiplicity (s = singlet, d = doublet, t 
= triplet, m = multiplet and/or multiplet resonances, b = broad), coupling constant (J) in Hertz (Hz) and 
integration. Mass spectra (LC-MS) were acquired using an Agilent 1100 LC-MSD VL system (G1946C) by 
direct injection with a 0.4 mL/min flow rate using a binary solvent system of 95/5 CH3OH/H2O. UV detection 
was monitored at 254 nm. Mass spectra were acquired in positive mode scanning over the mass range 105-
1500 m/z, using a variable fragmentor voltage of 10-70 mV. IR spectra were measured in KBr with a Perkin-
Elmer 398 spectrophotometer.  Elemental analysis for C, H, N and S was determined using Thermo Scientific 
Flash 2000 and results were within ±0.4% of the theoretical value. The purity of final products (7-11, 15, 23 
and 24) was 90% or higher and it was assessed by HPLC-MS, using a Kinetex EVO C18 column (00F-4633-
EO: 150 x 4.6 mm, 5 μm particle size) at a flow rate of 0.6 mL/min with an isocratic elution 60/50 v/v CH3CN 
/H2O (formic acid 0.5% v/v). UV detection was monitored at 254 nm. Mass spectra were acquired in positive 
mode scanning over the mass range 105-1500 m/z, using a fragmentor voltage of 0 mV. The MW-SPPS was 
performed using Fmoc strategy on a LibertyTM Microwave Peptide Synthesizer (CEM Corporation, Matthews, 
NC), an additional module of DiscoverTM (CEM Corporation, Matthews, NC) on a 0.10 mmol scale. Wang 
resin served as the solid support. It was preloaded with the first protected amino acid at a degree of 
functionalization of 0.60 mmol per gram of resin. The coupling was performed in DMF and the peptide chain 
assembled under computer control of the synthesizer. The synthesis cycles were composed of Fmoc-
deprotection and coupling, both under microwave irradiation. The deprotection was performed with 20% 
piperidine in DMF, the coupling mixture contained Fmoc-protected amino acid the activating agents HOBt (1-
Hydroxybenzotriazole) and HBTU (O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate) 
0.5 M in DMF and an excess of DIPEA (diisopropylethylamine) 34.8% v/v in DMF as the base. The final 
cleavage of the tripeptide from the solid support and the ester deprotection of the side chains was performed 
with 88% trifluoroacetic acid (TFA), 5% water, 2% triisopropylsilane (TIS) and 5% DL-Dithiothreitol (DTT) 
to quench reactive intermediates under microwave irradiation and to prevent the oxidation of the thioether side 
chain of methionine. The C-terminal end and the carboxylic aspartate side chain of the peptide is obtained as 
free carboxylic acids. All parameters (t, p, T, Q) have been estabilished automatically by the instrument and 
are different in every cycle. 
 
2.1 Synthetic procedures for the acid core 15. 
 (E)3-(4-Methylphenyl)-1-phenylpro-2-en-1-one (12) 
To a stirred solution of acetophenone (3.8 mL; 33.0 mmol) in absolute EtOH (50 mL), a solution of p-
tolualdehyde (3.8 mL; 33.0 mmol) in dry EtOH (50 mL) and a 4 N aqueous solution of NaOH (20.6 mL) were 
added. The mixture was stirred at room temperature for 6 h. The reaction was quenched with HCl 2 N and 
filtered, then the solvent was partially evaporated under vacuum. The residue was dissolved in AcOEt, washed 
with water, dried over Na2SO4, filtered and concentrated under reduced pressure. The solid obtained was 
decanted with EtOH furnishing the pure chalcone as a pale yellow solid. TLC Rf (Hexane/AcOEt 1/6) 0.70. 
Yield 99%. Mp: 189-190 °C. 1H-NMR (400 MHz CDCl3): δ (ppm) 7.97 (d, 2H, J = 7.6 Hz), 7.80 (d, 1H, J = 
15.6 Hz), 7.53 (m, 6H), 7.22 (d, 2H, J = 7.6 Hz), 2.38 (s, 3H). 13C-NMR (100 MHz CDCl3): δ (ppm) 190.27, 
144.74, 140.96, 138.29, 132.60, 132.09, 129.65, 128.52, 128.46, 128.43, 120.94, 21.45. LRMS (ESI) m/z = 
222.9 [M+H]⁺ ; 244.9 [M+Na]⁺ . IR (KBr): cm-1 3022 (CH=CH), 1656 (CO). Anal. calcd. for C16H14O: C 
86.45, H 6.35; found: C 86.47, H 6.45. 
4‐ (4‐ Methylphenyl)‐ 6‐ phenyl‐ 2‐ sulfanyl‐ 1,4‐ dihydropyridine‐ 3‐ carbonitrile (13) 
To a solution of sodium (186 mg, 8.10 mmol) in dry MeOH (22 mL) under N2 atmosphere, chalcone 12 (900 
mg, 4.05 mmol) and thiocyanoacetamide (405 mg, 4.05 mmol) were added. The mixture was stirred at reflux 
for 90 minutes. After cooling, the mixture was quenched with HCl 1 N and partially evaporated under vacuum. 
The residue was diluted in DCM, washed with water, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The pure yellow solid obtained was used directly in the next step.TLC Rf (Hexane/AcOEt 
4/1) 0.65. Yield 94%. Mp: 105-133 °C. 1H-NMR (400 MHz CDCl3): δ (ppm) 9.21 (s, 1H), 7.46 (m, 5H), 7.19 
(m, 4H), 5.92 (m, 0.4H), 5.78 (m, 0.6H), 4.33 (m, 0.4H), 4.09 (m, 0.6H), 2.35 (s, 3H), 2.04 (s, 1H). 13C-NMR 
(100 MHz): δ (ppm) 137.38, 132.95, 129.91, 129.74, 129.21, 128.04, 127.52, 125.34, 116.26, 108.90, 108.64, 
49.13, 48.38, 42.15, 21.04. LRMS (ESI) m/z = 304.9 [M+H]+; 326.8 [M+Na]+. IR (KBr) cm-1: 3203 (NH), 
2196 (CN). Anal. calcd. for C19H16N2S: C 74.97, H 5.30, N 9.20, S 10.53; found: C 74.86, H 5.68, N 8.84, S 
10.73. 
4‐ (4‐ Methylphenyl)‐ 6‐ phenyl‐ 2‐ sulfanylpyridine‐ 3‐ carbonitrile (14) 
To a stirred solution of 13 (679 mg, 2.23 mmol) in DCM (15 mL), DDQ (1014 mg, 4.46 mmol) was added. 
The mixture was stirred at room temperature for 3 h. The mixture was filtered and evaporated under reduced 
pressure. The dark solid obtained was decanted several times with MeOH, water and hexane to remove DDHQ. 
The solid was then recrystallized from MeOH. TLC Rf (Hexane/AcOEt 4/1) 0.43 Yield: 84%. Mp: 204-207 
°C. 1H-NMR (400 MHz CDCl3): δ (ppm) 7.96 (d, 2H, J = 8.0 Hz), 7.61 (s, 1H), 7.53 (d, 2H, J = 8.0 Hz), 7.37 
(m, 5H), 2.46 (s, 3H), 1.56 (s, 1H). 13C-NMR (100 MHz CDCl3): δ (ppm) 160.57, 158.83, 154.86, 142.72, 
140.58, 136.74, 132.85, 130.64, 129.76, 128.82, 128.27, 127.32, 117.35, 115.48, 21.31. LRMS (ESI) m/z = 
302.9 [M+H]+. IR (KBr) cm-1: 2215 (CN). Anal. calcd. for C19H14N2S: C 75.47, H 4.67, N 9.26, S 10.60; 
found: C 75.24, H 4.38, N 9.57, S 10.58. 
2‐ {[3‐ Cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐ yl]sulfanyl}acetic acid (15) 
To a stirred solution of 14 (418 mg, 1.38 mmol) in DMF (6 mL) a 10% aqueous solution of KOH (1.70 mL, 
3.04 mmol) and a solution of 2-bromoacetic acid (212 mg, 1.52 mmol) in DMF (1 mL) were added and the 
mixture was stirred at room temperature for 3 h. The mixture became dark red. Then the reaction was treated 
with HCl 3 N, becoming yellow, and extracted with AcOEt. The organic phase was washed with water, dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified through 
recrystallization from MeOH to give compound 15 as yellow crystal. TLC Rf (AcOEt/MeOH 9/1) 0.43. Yield: 
75%. Mp: 218-220 °C. 1H-NMR (400 MHz DMSO D6): δ (ppm) 8.25 (m, 2H), 7.88 (s, 1H), 7.65 (d, 2H, J = 
8.0 Hz), 7.51 (m, 3H), 7.39 (d, 2H, J = 8.0 Hz), 4.15 (s, 2H), 2.40 (s, 3H). 13C-NMR (100 MHz DMSO): δ 
(ppm) 170.29, 162.50, 158.40, 154.56, 140.47, 137.01, 133.11, 131.16, 129.84, 129.25, 128.97, 128.05, 
116.44, 116.12, 102.81, 33.37, 21.27. LRMS (ESI): m/z = 360.9 [M+H]+; 382.8 [M+Na]+; 398.9 [M+K]+. IR 
(KBr) cm-1: 3200-2400 (OH), 2219 (CN), 1710 (CO). Anal. calcd. for C21H16N2O2S: C 69.98, H 4.47, N 7.77, 
S 8.90; found: C 69.73, H 4.78, N 8.13, S 8.51. 
 
2.2. Synthetic procedure for monoamino acid adducts (7a-h and 8) 
General procedure for monoamino acid adducts (7a-h) 
To a stirred solution of 15 (50 mg, 0.14 mmol) in dry DMF (0.5 mL) at 0 °C under N2 atmosphere, the 
appropriate L-amino acid methyl ester (0.15 mmol), EDC (27 mg, 0.14 mmol), HOBt (19 mg, 0.14 mmol) and 
dry DIPEA (0.03 mL, 0.20 mmol) were added. The mixture was stirred 30 min at 0 °C and then 5 h at room 
temperature. The reaction was quenched with water and then extracted with AcOEt. The organic phase was 
washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue 
was purified through flash chromatography on silica gel. 
Methyl (2S)‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐ yl]sulfanyl}acetamido)‐
3‐  methylbutanoate   (L-Valine methyl ester adduct, 7a)  
Eluted with Hexane/AcOEt 3/1. Yield: 20%. White solid. 1H -NMR (400 MHz CDCl3): δ (ppm) 8.05 (m, 2H), 
7.60 (s, 1H), 7.53 (m, 5H), 7.35 (d, 2H, J = 7.6 Hz), 7.17 (d, 1H, J = 6.4 Hz), 4.48 (m, 1H), 4.08 (q, 2H, J = 
16 Hz), 3.53 (s, 3H), 2.44 (s, 3H), 1.97 (m, 1H), 0.69 (d, 3H, J = 6.8 Hz), 0.62 (d, 3H, J = 6.8 Hz). 13C-NMR 
(100 MHz CDCl3): δ (ppm) 167.92, 161.62, 158.97, 154.90, 140.65, 136.74, 132.83, 130.74, 129.75, 129.03, 
128.22, 127.39, 116.52, 115.36, 103.79, 57.34, 51.84, 33.89, 30.87, 29.59, 21.29, 18.60, 17.43. LRMS (ESI) 
m/z = 474.7 [M+H]⁺ ; 496.8 [M+Na]+. IR (KBr) cm-1: 3359 (NHCO), 2220 (CN), 1749 (CO ester), 1646 (CO 
amide). Anal. calcd. for C27H27N303S: C 68.48, H 5.75, N 8.87, S 6.77; found: C 68.37, H 5.59, N 8.77, S 
6.64.  
Methyl (2S)‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐ yl]sulfanyl}acetamido)‐
4‐  methylpentanoate (L-Leucine methyl ester adduct, 7b)   
Eluted with AcOEt/MeOH 9/1. Yield: 31%. White solid. Mp: 150-151 °C. 1H -NMR (400 MHz CDCl3): δ 
(ppm) 8.06 (d, 2H, J = 7.6 Hz), 7.60 (s, 1H), 7.52 (m, 5H), 7.34 (d, 2H, J = 7.6 Hz), 7.13 (d, 1H, J = 8.0 Hz), 
4.56 (m, 1H), 4.05 (q, 2H, J = 15.6 Hz), 3.54 (s, 3H), 2.44 (s, 3H), 1.40 (m, 2H), 1.26 (m, 1H), 0.31 (d, 3H, J 
= 11.4 Hz), 0.27 (d, 3H, J = 11.4 Hz). 13C-NMR (100 MHz CDCl3): δ (ppm) 172.73, 167.71, 161.64, 158.87, 
154.90, 140.6,6, 136.65, 132.82, 130.81, 129.78, 129.07, 128.20, 127.37 116.43, 103.77, 52.02, 50.81, 41.12, 
33.85, 24.53 22.50, 21.50, 21.31. LRMS (ESI) m/z = 407.7 [M+H]⁺ ; 509.8 [M+Na]+;525.5[M+K]+. IR (KBr) 
cm-1: 3362 (NHCO), 2222 (CN), 1745 (CO ester), 1650 (CO amide). Anal. calcd. for C28H29N3O3S: C 68.97, 
H 5.99, N 8.62, S 6.58; found: C 69.01, H 5.87, N 8.50, S 6.53. 
Methyl (2S,3S)‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐
yl]sulfanyl}acetamido)‐ 3‐  methylpentanoate (L-Isoleucine methyl ester adduct, 7c) 
Eluted with AcOEt/MeOH 9/1. Yield: 31%. White solid. Mp: 163-165 °C. 1H -NMR (400 MHz CDCl3): δ 
(ppm) 8.04 (m, 2H), 7.60 (s, 1H), 7.51 (m, 5H), 7.34 (d, 2H, J = 7.6 Hz), 7.18 (d, 1H, J = 8.4 Hz), 4.50 (m, 
1H), 4.06 (q, 2H, J = 15.6 Hz), 3.52 (s, 3H), 2.43 (s, 3H), 1.67 (m, 2H), 1.13 (m, 1H), 0.65 (m, 6H). 13C-NMR 
(100 MHz CDCl3): δ (ppm) 171.66, 167.78, 161.64, 158.96, 154.89, 140.66, 136.73, 132.82, 130.78, 129.76, 
129.04, 128.22, 127.40, 116.50, 115.37, 103.37, 56.68, 51.79, 37.51, 33.88, 24.83, 21.30, 15.07, 11.23. LRMS 
(ESI) m/z = 488.0 [M+H]⁺ ; 510.0 [M+Na]+;526.0[M+K]+. IR (KBr) cm-1: 3369 (NHCO), 2215 (CN), 1732 
(CO ester), 1657 (CO amide). Anal. calcd. for C28H29N3O3S: C 68.97, H 5.99, N 8.62, S 6.58; found: C 68.75, 
H 5.97, N 8.72, S 6.43. 
Methyl (2S)‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐ yl]sulfanyl}acetamido)‐
3‐  (1H‐ imidazol‐ 4‐ yl) propanoate (L-Histidine methyl ester adduct, 7d) 
Eluted with AcOEt/MeOH 9/1. Yield: 30%. White solid. Mp: 135-141 °C. 1H -NMR (400 MHz CDCl3): δ 
(ppm) 8.07 (m, 2H), 7.94 (d, 1H, J = 7.2 Hz), 7.57 (s, 1H), 7.52 (m, 5H), 7.39 (s, 1H), 7.34 (d, 2H, J = 8.0 Hz), 
6.62 (s, 1H), 4.80 (m, 1H), 4.11 (s, 2H), 3.54 (s, 3H), 2.89-3.02 (2q, 2H, J = 15.0 Hz), 2.44 (s, 3H), 1.50 (m, 
1H). 13C-NMR (100 MHz CDCl3): δ (ppm) 171.42, 167.99, 161.54, 158.70, 154.80, 140.08, 140.04, 136.77, 
133.10, 132.96, 130.74, 129.76, 129.02, 128.21, 127.42, 116.33, 115.62, 99.42, 90.97, 52.32, 52.21, 45.20, 
29.04, 21.28. LRMS (ESI) m/z = 512.0 [M+H]⁺ ; IR (KBr) cm-1: 3361 (NH), 2221 (CN), 1741 (CO ester), 
1654 (CO amide). Anal. calcd. for C28H25N5O3S: C 65.74, H 4.93, N 13.69, S 6.27; found: C 65.41, H 4.70, 
N 14.07, S 6.44. 
Methyl (2S)‐ 3‐ carbamoyl‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐
yl]sulfanyl}acetamido) propanoate  (L-Arginine methyl ester adduct, 7e) 
Eluted with DCM/MeOH 9/1. Yield: 27%. White solid. Mp: 161-171 °C. 1H -NMR (400 MHz CD3OD): δ 
(ppm) 8.19 (m, 2H), 7.74 (s, 1H), 7.57 (d, 2H, J = 8.0 Hz), 7.50 (m, 3H), 7.37 (d, 2H, J = 8.0 Hz), 4.45 (m, 
1H), 4.22 (q, 2H, J = 16.0 Hz), 3.59 (s, 3H), 3.02 (m, 2H), 2.43 (s, 3H), 1.62 (m, 1H), 1.82 (m, 1H), 1.47 (m, 
2H). 13C-NMR (100 MHz CD3OD): 171.90, 169.20, 161.91, 158.74, 154.86, 140.40, 136.90, 133.01, 132.02, 
130.40, 129.30, 129.25, 128.71, 128.17, 127.49, 126.60, 115.13, 48.16, 47.94, 47.09, 46.87, 40.29, 29.01, 
24.59. LRMS (ESI) m/z =  531.0 [M+H]⁺ ; 553.0 [M+Na]+. IR (KBr) cm-1: 3364 (NH), 2225 (CN), 1744 (CO 
ester), 1653 (CO amide). Anal. calcd. for C28H30N6O3S: C 63.38, H 5.70, N 15.84, S 6.04; found: C 63.44, H 
5.44, N 15.75, S 6.42. 
Methyl (2S)‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐ yl]sulfanyl}acetamido)‐
3‐  phenylpropanoate (L-Phenylalanine methyl ester adduct, 7f) 
Eluted with AcOEt/MeOH 9/1. Yield: 34%. White solid. Mp: 167-173 °C. 1H -NMR (400 MHz DMSO D6): 
δ (ppm) 8.65 (d, 1H, J = 7.6 Hz), 8.25 (m, 2H), 7.87 (s, 1H), 7.64 (d, 2H,  J = 7.6 Hz), 7.51 (m, 3H), 7.39 (d, 
2H, J = 7.6 Hz), 7.12 (m, 5H), 4.47 (m, 1H), 4.14 (s, 2H), 3.49 (s, 3H), 2.85-2.99 (2q, 2H, J = 14.0 Hz), 2.40 
(s, 3H). 13C-NMR (100 MHz DMSO D6): δ (ppm) 171.37, 167.67, 161.43, 158.77, 154.73, 140.71, 136.60, 
135.43, 132.88, 130.80, 129.84, 129.06, 128.71, 128.52, 128.21, 127.35, 126.80, 116.37, 115.32, 103.54, 
53.15, 52.12, 37.52, 33.38, 24.04. LRMS (ESI) m/z = 552.0 [M+H]⁺ ; 544.0 [M+Na]+; 560.0 [M+K]+. IR 
(KBr) cm-1: 3300 (NHCO), 2217 (CN), 1742 (CO ester), 1655 (CO amide). Anal. calcd. for C31H27N3O3S: C 
71.38, H 5.22, N 8.06, S 6.15; found:C 71.21, H 5.30, N 8.11, S 5.78. 
Methyl (2S)‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐ yl]sulfanyl}acetamido)‐
3‐  (4‐ methoxyphenyl) propanoate  (L-Tyrosine methyl ester adduct, 7g) 
Eluted with Hexane/AcOEt 6/4. Yield: 21%. White solid. Mp: 215-217 °C. 1H -NMR (400 MHz CDCl3): δ 
(ppm) 8.03 (m, 2H), 7.58 (d, 2H, J = 8 Hz), 7.50 (m, 3H), 7.36 (d, 2H, J = 7.6 Hz), 7.25 (s, 1H), 7.10 (d, 1H, 
J = 8.0 Hz), 6.68 (d, 2H, J = 8.2 Hz), 6.45 (d, 2H, J = 8.2 Hz), 5.12 (bs, 1H), 4.77 (m, 1H), 3.99 (q, 2H, J
 
= 
15.6 Hz), 3.57 (s, 3H), 2.75-2.94 (2q, 2H, J = 14.0 Hz), 2.45 (s, 3H). 13C-NMR (400 MHz CDCl3): δ (ppm) 
171.47, 167.80, 161.42, 158.90, 154.81, 144.96, 140.69, 136.59, 132.84, 130.94, 129.79, 129.12, 129.02, 
128.39, 127.57, 127.15, 116.56, 116.10, 115.40, 103.46, 53.17, 49.84, 36.58, 31.31, 21.29. LRMS (ESI) m/z 
= 538.0 [M+H]⁺ ; 540.6 [M+Na]+. IR (KBr) cm-1: 3400-3200 (OH), 3306 (NH), 2218 (CN), 1730 (CO ester), 
1656 (CO amide). Anal. calcd. for C31H27N3O4S: C 69.25, H 5.06, N 7.82, S 5.96; found: C 69.61, H 5.32, N 
7.99, S 5.83.  
1,5‐ Dimethyl (2S)‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐
yl]sulfanyl}acetamido) pentanedioate (L-Glutammate methyl diester adduct, 7h) 
Eluted with Hexane/AcOEt 1/1. Yield: 27%. White solid. Mp: 179-193 °C. 1H -NMR (400 MHz CDCl3): δ 
(ppm) 8.06 (m, 2H),  7.61 (s, 1H),  7.54 (d, 2H, J = 7.6 Hz), 7.50 (m, 3H), 7.35 (d, 2H, J = 7.6 Hz), 7.25 (s, 
1H), 4.58 (m, 1H), 4.05 (q, 2H, J
 
= 15.8 Hz), 3.55 (s, 3H), 3.54 (s, 3H), 2.44 (s, 3H), 2.09 (m, 2H), 1.78 (m 
2H). 13C-NMR (400 MHz CDCl3): δ (ppm) 171.30, 168.01, 162.70, 161.80, 158.97, 155.00, 140.66, 136.66, 
132.85, 130.80, 129.78, 129.11, 128.29, 127.47, 116.61, 115.37, 103.86, 59.91, 59.12, 53.05, 52.20, 41.80, 
37.02, 20.50. LRMS (ESI) m/z = 518.0 [M+H]⁺ ; 540.0 [M+Na]+; 556.0 [M+K]⁺ . IR (KBr) cm-1: 3312 
(NHCO), 2215 (CN), 1732 (CO ester), 1653 (CO amide). Anal. calcd. for C28H27N3O5S: C 64.97, H 5.26, N 
8.12, S 6.20; found: C 65.01, H 5.43, N 8.49, S 6.06. 
(2S)‐ 2‐ (2‐ {[3‐ Cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐ yl]sulfanyl}acetamido)‐ 3‐
methylbutanoic acid (L-Valine free acid adduct, 8)  
To a stirred solution of 7a (24 mg, 0.05 mmol) in a 3/1/0.5 mixture of THF/EtOH/H2O (2 mL), NaOH 1 N 
(0.22 mL, 0.22 mmol) was added. The mixture was stirred at room temperature for 15 min until the solution 
becomes yellow. The reaction was quenched with HCl 2 N and extracted with AcOEt. The organic phase was 
washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue 
was purified through flash chromatography on silica gel, eluting with AcOEt/MeOH/AcOH 9/1/0.5 to give 
pure 8. TLC Rf (DCM/MeOH 9/1) 0.61. Yield: 40%. 1H-NMR (400 MHz CD3OD): δ (ppm) 8.19 (d, 2H, J = 
8.0 Hz), 7.76 (s, 1H), 7.58 (d, 2H, J = 8.0 Hz), 7.50 (m, 3H), 7.38 (d, 2H, J = 8.0 Hz), 4.24 (d, 1H, J = 16.0 
Hz), 4.17 (q, 2H, J = 16.0 Hz), 2.44 (s, 3H), 2.06 (m, 1H), 0.74 (d, 3H, J = 16.0 Hz), 0.73 (d, 3H, J = 16.0 Hz). 
13C-NMR (100 MHz CD3OD): δ (ppm) 174.15, 171.31, 162.55, 158.39, 154.47, 140.11, 137.09, 133.22, 
131.31, 129.74, 129.31, 128.80, 128.15, 116.41, 116.21, 102.78, 31.10, 30.40, 23.40, 21.30, 18.99. LRMS 
(ESI) m/z = 459.8 [M+H]+; 481.8 [M+Na]+. IR (KBr) cm-1: 3450-3100 (OH), 3362 (NHCO), 2221 (CN), 1690 
(CO acid), 1646 (CO amide). Anal. calcd. for C26H25N303S: C 67.95, H 5.48, N 9.14, S 6.98; found: C 68.02, 
H 5.33, N 8.96, S 6.79. 
 
2.3. Synthetic procedure for diamino acid adducts (9 and 10) 
1,4‐ Dimethyl(2S)‐ 2‐ [(2S)‐ 2‐ ({[(9H‐ fluoren‐ 9‐ yl)methoxy]carbonyl}amino)‐ 3‐
methylbutanamido] butanedioate  (Fmoc-Val-Asp-OMe(OMe), 16)  
Same amidation protocol used for 7a-h: To a stirring solution of Fmoc-Valine (500 mg, 1.47 mmol) in dry 
DMF (5 mL) a solution of L-aspartate dimethyl ester (hydrochloride salt; 291 mg, 1.47 mmol) in dry DMF (53 
mL) was added dropwise at 0 °C under N2 atmosphere. Then EDC (282 mg, 1.47 mmol), HOBt (199 mg, 1.47 
mmol) and dry DIPEA (0.31 mL, 1.77 mmol) were added. The mixture was stirred 30 min at 0 °C and then 4 
h at room temperature. The reaction was quenched with water and then it was extracted with AcOEt. The 
organic phase was washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude residue was purified through flash chromatography on silica gel. Eluted with Hexane/AcOEt 1/1. 
TLC Rf (Hexane/AcOEt 1/1) 0.55. Yield: 79%. 1H-NMR (400 MHz CDCl3): δ (ppm) 7.74 (d, 2H, J = 8.0 
Hz), 7.58 (d, 2H, J = 6.4 Hz), 7.38 (t, 2H, J = 7.2 Hz), 7.29 (t, 2H, J = 7.2 Hz), 6.92 (d, 1H, J = 7.6 Hz), 5.56 
(d, 1H, J = 8.4), 4.89 (m, 1H), 4.37 (m, 2H), 4.21 (t, 1H, J = 6.8 Hz), 4.10 (m, 1H), 3.73 (s, 3H), 3.66 (s, 3H), 
3.04 (dd, 1H, J = 13.6 Hz), 2.83 (dd, 1H, J = 4.4 Hz, J = 17.2 Hz), 2.13 (m, 1H), 0.99 (d, 3H, J = 6.0 Hz), 0.96 
(d, 3H, J = 6.0 Hz). 13C-NMR (100 MHz CDCl3) δ (ppm) 171.08, 170.70, 156.23, 143.71, 141.21, 127.62, 
126.99, 125.08, 119.79, 67.10, 60.06, 52.68, 52.04, 48.32, 47.06, 35.80, 31.44, 18.88, 17.62 LRMS (ESI) m/z 
= 483.0 [M+H]+; 505.2 [M+Na]+. IR (KBr) cm-1: 3362 (NHCO), 1745 (CO ester), 1649 (CO amide). Anal. 
calcd. for C26H30N207: C 64.72, H 6.27, N 5.81; found: C 64.51, H 6.25, N 6.09. 
1,4‐ Dimethyl (2S)‐ 2‐ [(2S)‐ 2‐ amino‐ 3‐ methylbutanamido]butanedioate (NH2-Val-Asp-
OMe(OMe), 17) 
To a stirred solution of 16 (271 mg, 0.56 mmol) in DMF (7 mL), NaN3 (73 mg, 1.12 mmol) was added. The 
mixture was stirred at 50 °C for 12 h. The reaction was quenched with water and extracted with AcOEt. The 
organic phase was washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude residue was used in the next step without further purification. TLC Rf (Hexane/AcOEt 3/1) 0.57. 
LRMS (ESI) m/z = 261.8 [M+H]+.  
1,4‐ Dimethyl (2S)‐ 2‐ [(2S)‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐
yl]sulfanyl} acetamido)‐ 3‐  methylbutanamido]butanedioate  (Diamino acid methyl diester adduct, 9) 
Same amidation protocol used for 7a-h: To the crude of 17a, dry DMF (3 mL) was added under N2 atmosphere. 
Then a solution of 15 (112 mg, 0.31 mmol) in dry DMF (3 mL) was added dropwise at 0 °C. EDC (42 mg, 
0.31 mmol), HOBt (59 mg, 0.31 mmol) and dry DIPEA (0.06 mL, 0.37 mmol) were added. The mixture was 
stirred 30 min at 0 °C and then 12 h at room temperature. The reaction was quenched with water and then it 
was extracted with AcOEt. The organic phase was washed with water, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude residue was purified through flash chromatography on silica 
gel. Eluted with AcOEt. TLC Rf (AcOEt) 0.56. Yield: (over two steps): 21%. 1H NMR (400 MHz CDCl3): δ 
(ppm) 8.04 (d, 2H, J = 6.0 Hz), 7.58 (s, 1H), 7.53 (m, 2H), 7.48 (m, 3H), 7.30 (m, 2H), 6.79 (d, 1H, J = 8.0 
Hz), 4.73 (m, 1H), 4.25 (t, 1H, J = 7.2 Hz), 4.16 (d, 1H, J = 15.6 Hz), 4.00 (d, 2H, J = 15.6 Hz), 3.69 (s, 3H), 
3.64 (s, 3H), 2.91 (dd, 1H, J = 17.2 Hz), 2.62 (dd, 1H, J = 4.4 Hz, J = 17.2 Hz), 2.43 (s, 3H), 1.93 (m, 1H), 
0.75 (d, 3H, J = 6.8 Hz), 0.67 (d, 3H, J = 6.8 Hz). 13C-NMR (100 MHz CDCl3): δ (ppm) 171.08, 170.70, 
156.23, 143.85, 130.73, 129.97, 129.76, 129.04, 128.23, 127.40, 116.58, 115.37, 79.41, 58.60, 52.67, 52.02, 
48.15, 35.65, 31.82, 29.59, 29.24, 26.30, 22.58. 21.28, 18.66, 17.54, 14.01. LRMS (ESI) m/z = 602.8 [M+H]+; 
624.8 [M+Na]+. IR (KBr) cm-1: 3361 (NHCO), 2225 (CN), 1742 (CO ester), 1651 (CO amide). Anal. calcd. 
for C32H34N406S: C 63.77, H 5.69, N 9.30, S 5.32; found: C 63.81, H 5.75, N 9.09, S 5.64 
(2S)‐ 2‐ [(2S)‐ 2‐ (2‐ {[3‐ Cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐
yl]sulfanyl}acetamido)‐ 3‐ methylbutanamido]butanedioic acid (Diamino acid acid free adduct, 10) 
To a stirred solution of 9 (34 mg, 0.05 mmol) in a 3/1/0.5 mixture of THF/EtOH/H2O (2 mL), NaOH 1 N (0.22 
mL, 0.22 mmol) was added. The mixture was stirred at room temperature for 15 min until the solution becomes 
yellow. The reaction was quenched with HCl 2 N and extracted with AcOEt. The organic phase was washed 
with water, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was 
purified through flash chromatography on silica gel, eluting with AcOEt/MeOH/AcOH 9/1/0.5 to give pure 
10. TLC Rf (AcOEt) 0.41. Yield: 61%. 1H-NMR (400 MHz CD3OD): δ (ppm) 8.04 (d, 2H, J = 6.8Hz), 7.56 
(s, 1H), 7.54 (m, 3H), 7.40 (m, 4H), 4.65 (t, 1H, J = 5.6 Hz), 4.41 (m, 1H), 3.83 (m, 1H), 3.16 (m, 1H), 2.20 
(m, 2H), 1.02 (d, 3H, J = 7.2 Hz), 1.01 (d, 3H, J = 7.2 Hz). 13C-NMR (100 MHz CD3OD): δ (ppm) 173.08, 
171.90, 165.58; 160.06, 156.68, 148.15, 145.94, 139.17, 137.92; 129.29; 128.42; 128.23; 127.72; 126.88; 
121.38; 118.27, 98.30, 63.48, 58.54, 49.71, 36.71, 30.82, 29.25, 19.87, 18.39, 17.39. LRMS (ESI) m/z = 574.9 
[M+H]+; 573.0 [M-H]. IR (KBr) cm-1: 3420-3090 (OH), 3361 (NHCO), 2225 (CN), 1688 (CO acid), 1640 
(CO amide). Anal. calcd. for C30H30N406S: C 62.70, H 5.26, N 9.75, S 5.58; found: C 62.80, H 5.35, N 9.89, 
S 5.62. 
 
2.4. Synthetic procedure for triamino acid adduct (11) 
(2S)‐ 2‐ [(2S)‐ 3 Carboxy‐ 2‐ [(2S)‐ 2‐ ({[(9H‐ fluoren‐ 9‐ yl)methoxy]carbonyl}amino)‐ 3‐
methylbutanamido] propanamido]‐ 4‐ (methylsulfanyl)butanoic acid (Resin-free Fmoc-tripeptide, 19) 
Resin-bounded compound 18 was charged in a gooch filter and treated with a 88/2/5/5 cleavage solution of 
TFA/TIPS/H2O/DTT (20 mL) under an upward flux of N2. After 1 h the resin was filtered and the filtrate was 
recovered and evaporated under reduced pressure. The white solid obtained was washed with hexane and 
toluene and used directly in the next step. 
Resin-bounded tripeptide (18) 
Compound 18 has been obtained by MW-SPPS (microwave solid phase peptide synthesis) using an MW 
automated CEM Peptide Synthesizer. The instrument has been charged with Fmoc-methionine on Wang resin 
(167 mg) previously swallowed in DMF through a fritted buchner funnel under N2 flux for 2 h. The instrument 
was also charged with: Fmoc-Val-OH (2N, 408 mg in 6 mL of DMF); Fmoc- Asp(OtBu)-OH (2N, 492 mg in 
6 mL of DMF); a HOBt and HBTU (270 mg and 758 mg respectively in 4 mL of DMF); DIPEA (2 mL of 34.8 
% v/v DMF); piperidine (100 mL of 20% v/v DMF); DCM (2 L); DMF (2 L). Then the instrument was set and 
the synthetic procedure lasted for 3 h and 37 min. The obtained resin was removed from the instrument and 
washed several times with DMF and DCM.  
Methyl (2S)‐ 2‐ [(2S)‐ 2‐ [(2S)‐ 2‐ ({[(9H‐ fluoren‐ 9‐ yl)methoxy]carbonyl}amino)‐ 3‐
methylbutanamido]‐ 4‐  methoxy‐ 4‐ oxobutanamido]‐ 4‐ (methylsulfanyl)butanoate (methyl diester 
Fmoc-tripeptide, 20) 
To a stirred solution of 19 (170 mg, 0.29 mmol) in dry MeOH (10 mL), freshly distilled SOCl2 (0.22 mL, 2.90 
mmol) was added at 0 °C. The mixture was stirred at 0 °C for 30 min and then at room temperature for 6 h. 
Solvent was removed under reduced pressure. The crude residue was purified through flash chromatography 
on silica gel, eluting with AcOEt to give 20. TLC Rf (AcOEt) 0.69. Yield: 28%. 1H-NMR (400 MHz CDCl3): 
δ (ppm) 7.75 (d, 2H, J = 7.6 Hz), 7.58 (d, 2H, J = 7.2 Hz), 7.39 (t, 2H, J = 7.6 Hz), 7.31 (t, 2H, J = 7.6 Hz), 
5.40 (m, 1H), 4.82 (m, 1H), 4.62 (m, 1H), 4.44 (m, 2H), 4.23 (t, 1H, J = 6.8 Hz), 4.00 (m, 1H), 3.72 (s, 3H), 
3.68 (s, 3H), 3.04 (m, 1H), 2.99 (m, 1H), 2.67 (t, 2H, J = 6.4 Hz), 2.53 (m, 2H), 2.16 (s, 3H), 1.99 (m, 1H), 
0.98 (d, 3H), 0.95 (d, 3H). 13C-NMR (100 MHz DMSO): δ (ppm) 172.91, 170.70, 170.31, 156.23, 143.71, 
141.21, 127.62, 126.99, 125.08, 119.98, 119.79, 67.10, 65.69, 60.06, 55.11, 52.04, 51.89, 48.32, 47.06, 35.80, 
31.44, 31.00, 27.91, 18.88, 17.62, 15.47. LRMS (ESI) m/z = 613.7 [M+H]+; 636.7 [M+ Na]+; 652.0 [M+ K]+. 
IR (KBr) cm-1: 3361 (NHCO), 1742 (CO ester), 1651 (CO amide). Anal. calcd. for C31H39N308S: C 60.67, H 
6.41, N 6.85, S 5.22; found: C 60.42, H 6.35, N 7.09, S 5.44. 
Methyl (2S)‐ 2‐ [(2S)‐ 2‐ [(2S)‐ 2‐ amino‐ 3‐ methylbutanamido]‐ 4‐ methoxy‐ 4‐
oxobutanamido]‐ 4‐  (methylsulfanyl) butanoate  (Free amine tripeptide, 21)  
Same deprotection protocol used for 17. To a stirred solution of 20 (48 mg, 0.79 mmol) in DMF (a mL), NaN3 
(13 mg, 0.20 mmol) was added. The mixture was stirred at 50 °C for 4 h. The reaction was quenched with 
water and extracted with AcOEt. The organic phase was washed with water, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude residue was purified through flash chromatography on silica 
gel, eluting with AcOEt/MeOH 9/1 to give 21. TLC Rf (AcOEt) 0.47. Yield: 62%. LRMS (ESI) m/z = 391.8 
[M+H]+; 414.0 [M+ Na]+; 430.1 [M+ K]+. IR (KBr) cm-1: 3401 (NH), 3361 (NHCO), 1742 (CO ester), 1651 
(CO amide). Anal. calcd. for C16H29N306S: C 49.09, H 7.47, N 10.73, S 8.19; found: C 49.24, H 7.38, N 10.89, 
S 8.44. 
Methyl (2S)‐ 2‐ [(2S)‐ 2‐ [(2S)‐ 2‐ (2‐ {[3‐ cyano‐ 4‐ (4‐ methylphenyl)‐ 6‐ phenylpyridin‐ 2‐
yl]sulfanyl} acetamido)‐  3‐ methylbutanamido]‐ 4‐ methoxy‐ 4‐ oxobutanamido]‐ 4‐
(methylsulfanyl)butanoate (Tripeptide methyl diester adduct, 11) 
Same amidation protocol used for 7a-h. To a stirring solution of 21 (7 mg, 0.02 mmol) in dry DMF (1 mL) a 
solution of 15 (6 mg, 0.02 mmol) in dry DMF (0.5 mL) was added dropwise at 0 °C under N2 atmosphere. 
Then EDC (3 mg, 0.02 mmol), HOBt (2 mg, 0.02 mmol) and dry DIPEA (0.01 mL, 0.02 mmol) were added. 
The mixture was stirred 30 min at 0 °C and then 12 h at room temperature. The reaction was quenched with 
water and then extracted with AcOEt. The organic phase was washed with water, dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude residue was purified through flash chromatography on 
silica gel, eluting with AcOEt to give 11. Yield: 41%. 1H-NMR (400 MHz CD3OD): δ (ppm) 8.19 (d, 2H, J = 
2.4 Hz), 7.77 (s, 1H), 7.60 (d, 2H, J = 8.0 Hz), 7.51 (m, 3H), 7.38 (d, 2H, J = 8.0 Hz), 4.94 (m, 1H), 4.52 (m, 
1H), 4.43 (m, 1H), 3.70 (m, 2H), 3.30 (s, 6H), 2.94 (d, 1H, J = 8.0 Hz), 2.90 (d, 1H, J = 8.0 Hz), 2.54 (m, 2H), 
2.53 (m, 1H), 2.44 (s, 3H), 2.29 (m, 2H), 2.00 (s, 3H), 0.81 (d, 3H, J = 6.8 Hz), 0.76 (d, 3H, J = 76.8 Hz). 13C-
NMR (100 MHz DMSO): δ (ppm) 172.09, 171.65,156.25, 143.70, 130.69, 129.97, 129.76,129.04, 128.25, 
127.50, 116.45, 115.37, 79.41, 58.60, 55.10, 52.00, 48.15, 35.65, 31.82, 31.09, 29.59,29.31, 29.24, 26.30, 
23.33, 22.49. 21.28, 18.66, 17.54, 15.13, 14.01. IR (KBr) cm-1: 3369 (NHCO), 2218 (CN), 1749 (CO ester), 
1647 (CO amide). Anal. calcd. for C37H43N507S2: C 60.55, H 5.91, N 9.54, S 8.74; found: C 60.41, H 6.15, N 
9.59, S 8.84. 
Tert-butyl (hydroxymethyl)carbamate (22) 
t-butoxy carbamide (300 mg, 2.56 mmol), water (2 mL), formaldehyde (37% in H2O, 0.52 mL, 6.41 mmol) 
and K2CO3 (7 mg, 0.05 mmol) were charged into a round bottomed flask with a magnetic stirrer. The mixture 
was heated to 65 °C and stirred for 1 h. After cooling the mixture was extracted with AcOEt. The organic 
phase was washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
residue was purified through flash chromatography on silica gel, eluting with Hexane/AcOEt 3/2 to give 
compound 23b as white solid. Yield: 42%. 1H-NMR (400 MHz CDCl3): δ (ppm) 5.93 (s, 1H), 4.59 (s, 2H), 
4.39 (s, 1H), 1.39 (s, 9H). 13C-NMR (100 MHz CDCl3): δ (ppm) 156.07, 80.02, 65.41, 28.19. LRMS (ESI) 
m/z = 169.9 [M+Na] +. IR (KBr) cm-1: 3402-3195 (OH), 3360 (NHCO), 1755 (CO ester), 1640 (CO amide). 
Anal. calcd. for C6H13NO3: C 48.97, H 8.90, N 9.52; found: C 48.84, H 8.85, N 9.44. 
Tert-butyl (((3-cyano-6-phenyl-4-(p-tolyl)pyridin-2-yl)thio)methyl)carbamate (23) 
To a stirred solution of compound 23 (80 mg, 0.54 mmol) in DCM (1 mL), triphenylphosphine (PPh3) (214 
mg, 0.81 mmol) was added. The mixture was cooled in an ice-bath and CBr4 (334 mg, 1.09 mmol) was added. 
The mixture was irradiated with MW for 15 min at 40 °C. The solution obtained was added dropwise to 14 
(82 mg, 0.27 mmol) and trimethylamine (0.07 mL, 0.54 mmol) in DCM (2 mL). The mixture was stirred at 
room temperature for 12 h. The reaction was quenched with water and extracted with DCM. The organic phase 
was washed with water, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
residue was purified through flash chromatography on silica gel, eluting with Hexane/AcOEt 9/1 give 
compound 23. Yield: 49%. 1H-NMR (400 MHz CDCl3): δ (ppm) 8.03 (m, 2H), 7.55 (s, 1H), 7.52 (m, 5H), 
7.39 (d, 2H, J = 8.0 Hz), 5.77 (s, 1H), 5.11 (d, 2H, J = 4.0 Hz), 2.43 (s, 3H), 1.49 (s, 9H). LRMS (ESI) m/z = 
432.8 [M+H]+. IR (KBr) cm-1: 3360 (NHCO), 2218 (CN), 1755 (CO ester), 1640 (CO amide). Anal. calcd. 
for C25H25N302S: C 69.58, H 5.84, N 9.74, S 7.43; found: C 69.60, H 5.95, N 9.81, S 7.74. 
2-((3-cyano-6-phenyl-4-(p-tolyl)pyridin-2-yl)thio)acetamide (24) 
To a stirred solution of 2-mercapto-pyridine 14 (120 mg, 0.40 mmol) in DMF (2 mL) a 10% aqueous solution 
of KOH (0.15 mL, 0.27 mmol) was added and the mixture was stirred at room temperature for 30 min. The 
mixture becomes red and then a solution of 2-Bromoacetamide (60 mg, 0.40 mmol) in DMF (0.5 mL) was 
added dropwise. The mixture was stirred for further 3h at room temperature. The reaction was treated with 
HCl 1 N and extracted with AcOEt. The organic phase was washed with water, dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude residue was purified through flash chromatography on 
silica gel, eluting with Hexane/AcOEt 1/1 to give compound 24 as pale yellow solid. Yield: 50%. 1H-NMR 
(400 MHz CDCl3): δ (ppm) 8.08 (d, 2H, J = 8.0 Hz), 7.50 (s, 1H), 7.48-7.44 (m, 3H), 7.38-7.31 (m, 4H), 5.96 
(bs, 2H), 5.70 (s, 2H), 2.45 (s, 3H). 13C-NMR (100 MHz CDCl3): δ (ppm) 170.54, 162.50, 158.40, 154.56, 
140.47, 137.01, 133.11, 131.16, 129.66, 129.25, 128.97, 128.05, 116.44, 116.12, 102.42, 33.37, 21.27. LRMS 
(ESI) m/z = 359.8 [M+H]+; 381.8 [M+Na]+. IR (KBr) cm-1: 3300 (NHCO), 2218 (CN) 1644 (CO amide). 
Anal. calcd. for C21H17N30S: C 70.17, H 4.77, N 11.69, S 8.92; found: C 69.98, H 4.95, N 11.77, S 8.74. 
 
3. BIOLOGY SECTION 
Cells and Virus. Human embryonic kidney 293T (HEK 293T) and Madin−Darby canine kidney (MDCK) 
cells were cultivated in Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies) supplemented with 
10% (v/v) fetal bovine serum (FBS, Life Technologies) and antibiotics (100 U/mL penicillin and 100 μg/mL 
streptomycin, Life Technologies). The cells were maintained at 37 °C in a 5% CO2 humidified atmosphere. 
Influenza A/PR/8/34 virus (PR8 strain, H1N1, Cambridge lineage) was obtained from P. Digard (Roslin 
Institute, University of Edinburgh, United Kingdom). 
Compounds and Peptide. Ribavirin (RBV; 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) and oseltamivir 
carboxylic acid (OSV), the active form of oseltamivir [(3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-
1-cyclohexene-1-carboxylic acid] were obtained from Roche. The PB11–15–Tat peptide was synthesized and 
purified by the Peptide Facility of CRIBI Biotechnology Center (University of Padua, Padua, Italy). The PB11–
15–Tat peptide possesses a C-terminal sequence from the HIV Tat protein (amino acids 47–59) to mediate cell 
entry. 
PA−PB1 Interaction Enzyme-Linked Immunosorbent Assay (ELISA). The PA−PB1 interaction was 
detected as described by Trist et al.[71] Briefly, microtiter plates (Nuova Aptca) were incubated with 400 ng 
of 6His-PA(239−716) for 3 h at 37 °C and then blocked with 2% BSA (Sigma) in PBS for 1 h at 37 °C. After 
washing, 200 ng of GST-PB1(1−25) or GST as a control, dissolved in serum-free DMEM, in the presence of test 
compounds at various concentrations or DMSO, were added and incubated overnight at room temperature. E. 
coli-expressed, purified 6His-PA(239−716), GST, and GST-PB1(1−25) proteins were obtained as previously 
described.[50,88] After washing, the interaction between 6His−PA(239−716) and GST−PB1(1−25) was detected 
with an anti-GST monoclonal antibody conjugated to horseradish peroxidase (HRP; GenScript). After the final 
wash step, the substrate 3,3′,5,5′-tetramethylbenzidine (TMB, KPL) was added, and the optical density was 
determined at 450 nm by an ELISA plate reader (Tecan Sunrise). Values obtained from the samples treated 
with only DMSO were used to set as 100% of PA−PB1 interaction. The PB1(1−15)-Tat peptide was included in 
all experiments as positive control for inhibition. 
Plaque Reduction Assay (PRA). Antiviral activity of compounds was investigated using PRAs, as described 
elsewhere.[89] Briefly, a confluent monolayer of MDCK cells was seeded in 12-well plates. Cells were 
infected with FluA virus (PR8 strain) at 40 PFU/well in DMEM supplemented with 1 μg/mL of TPCK-treated 
trypsin (Worthington Biochemical Corporation) and 0.14% BSA in the presence of various concentrations of 
test compounds for 1 h at 37 °C. Medium containing 1 μg/mL of TPCK-treated trypsin, 0.14% BSA, 1.2% 
Avicel, and test compounds at the same concentrations was then added. After 2 days of incubation, cell 
monolayers were fixed with 4% formaldehyde and stained with 0.1% toluidine blue, and viral plaques were 
counted. Ribavirin and oseltamivir carboxylic acid were included in all experiments as reference compounds. 
The mean plaque number obtained from the samples treated with DMSO was set at 100%. 
Cytotoxicity Assay. Cytotoxicity of test compounds was assessed in MDCK and HEK 293T cells by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, as previously reported.[90,91] 
Briefly, MDCK cells (5 × 103 cells/well on 96-well plates) and HEK 293T (2 × 104 cells/well on 96-well plates) 
cells were incubated with test compounds at 2-fold serial dilutions from 250 μM or DMSO. After 24 or 48 h 
for HEK 293T and MDCK cells, respectively, MTT solution (5 mg/mL in PBS) was added to each well, and 
plates were incubated for 4 h at 37 °C. Then, a solubilization solution was added to lyse cells. After 3 h of 
further incubation at 37 °C, absorbance was read at 620 nm using an ELISA plate reader (Tecan Sunrise). 
Values obtained from the wells treated with only DMSO were used to set as 100% of viable cells. 
Minireplicon Assay. HEK 293T cells were seeded at a density of 2 × 105 per well into 24-well plates. After 
24 h, cells were transfected with pcDNA-PB1, pcDNA-PB2, pcDNA-PA, and pcDNA-NP plasmids (100 
ng/well of each), expressing the Flu A/PR/8/34 virus PB1, PB2, PA, and NP proteins, respectively, along with 
pPolI-Flu-ffLuc plasmid (50 ng/well), containing an influenza virus-based luciferase minireplicon vRNA 
under the control of the human RNA polymerase I promoter. Plasmids pcDNA-PB1, pcDNA-PB2, pcDNA-
PA, and pcDNA-NP were generated as described elsewhere[92] and were  kindly provided by P. Digard 
(Roslin Institute, University of Edinburgh, United Kingdom), whereas the plasmid pPolIFlu-ffLuc was 
provided by L. Tiley (University of Cambridge, United Kingdom). The transfection mixture also contained 
pRL-SV40 plasmid (50 ng/well. Promega), which constitutively expresses the Renilla luciferase, to normalize 
variations in transfection efficiency. Transfections were performed using calcium phosphate protocol in the 
presence of the test compounds or DMSO. Cell medium was replaced 4 h post-transfection with DMEM 
containing compounds or DMSO. At 24 h post-transfection, cells were harvested and both firefly luciferase 
and Renilla luciferase expression were determined using the Dual Luciferase Assay Kit from Promega. 
Ribavirin was included in all experiments as the reference compound. 
Interference compound assessment. The behaviour of all the tested compounds (7-11, 15, 23 and 24) as 
PAINS (Pan-Assay Interference Compounds) [93] was examined through prediction by the online 
FAFDrugs4[94–96] (Free ADME-Tox Filtering Tool) program. Through its tool Bank-Formatter the 
compound library was prepared and then screened with the three different available filters A, B and C. All the 
analysed compounds resulted “accepted” by the software.[97] 
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